Iambic, an AI Drug Discovery Specialist, Banks $150M in an IPO
4 Articles
4 Articles
According to ChainCatcher, Iambic Therapeutics, in which Nvidia holds a stake, completed its initial public offering (IPO) in the United States, raising $150 million at a price of $16 per share, issuing approximately 9.38 million shares. The company's market capitalization reached $758 million, and the funds raised will be used to advance three early-stage cancer drugs.
Iambic Announces Pricing of Initial Public Offering
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today announced the pricing of its initial public offering of 9,375,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Iambic. The gross proceeds from the offering, before deducting …
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
